

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (Previously Presented) A method for the treatment of established joint inflammation in a patient in need thereof comprising administering to the patient an effective anti-inflammatory amount of a composition comprising a purified antibody specific against C5.
2. (Previously Presented) The method of Claim 1 wherein the composition is administered in an amount effective to inhibit the cell-lysing capability of complement present in a blood-derived fluid of the patient.
3. (Previously Presented) The method of Claim 2 wherein the blood-derived fluid is serum.
4. (Previously Presented) The method of Claim 1 wherein the composition is administered in an amount effective to reduce the level of soluble C5b-9 present in a blood-derived fluid of the patient after activation of complement in that fluid.
5. (Previously Presented) The method of Claim 4 wherein the blood-derived fluid is serum.
6. (Previously Presented) The method of Claim 1 wherein the composition is administered in an amount effective to reduce the level of C5a present in a blood-derived fluid of the patient after activation of complement in that fluid.
7. (Previously Presented) The method of Claim 6 wherein the blood-derived fluid is serum.

8. (Previously Presented) The method of Claim 1 wherein the composition is administered in an amount effective to reduce the cell-lysing ability of complement present in the synovial fluid of an inflamed joint of the patient by at least 10%.
9. (Previously Presented) The method of Claim 1 wherein the composition is administered in an amount effective to reduce the level of soluble C5b-9 present in the synovial fluid of an inflamed joint of the patient by at least 10%.
10. (Previously Presented) The method of Claim 1 wherein the composition is administered in an amount effective to reduce the level of C5a present in the synovial fluid of an inflamed joint of the patient by at least 10%.
11. (Previously Presented) The method of Claim 1 comprising the further step, after the administration of the composition, of determining the C5a level and/or the C5b level in the synovial fluid of an inflamed joint of the patient so as to monitor the course of the patient's response to the administration of the composition.
12. (Previously Presented) The method of Claim 11 wherein the C5a level is determined by an immunoassay or a chemotaxis assay.
13. (Previously Presented) The method of Claim 11 wherein the C5b level is determined by measuring the level of soluble C5b-9 in the synovial fluid or by measuring the cell-lysing ability of complement present in the synovial fluid.

14. (Previously Presented) The method of Claim 1 wherein the composition does not interfere with the cleavage of complement component C3 in the patient's serum into C3a and C3b.
15. – 16. (Cancelled)
17. (Previously Presented) The method of Claim 1, wherein said antibody is a monoclonal antibody.
18. (Currently Amended) The method of Claim ~~18~~ 17, wherein said monoclonal antibody is 5G1.1 (ATCC Accession No. HB-11625).
19. (Previously Presented) A method for the treatment of established joint inflammation in a patient in need thereof comprising administering to the patient an effective anti-inflammatory amount of a composition comprising a purified antibody, which binds the alpha chain of C5.
20. (Previously Presented) The method of Claim 19 wherein the composition is administered in an amount effective to inhibit the cell-lysing capability of complement present in a blood-derived fluid of the patient.
21. (Previously Presented) The method of Claim 20 wherein the blood-derived fluid is serum.
22. (Previously Presented) The method of Claim 19 wherein the composition is administered in an amount effective to reduce the level of soluble C5b-9 present in a blood-derived fluid of the patient after activation of complement in that fluid.

23. (Previously Presented) The method of Claim 22 wherein the blood-derived fluid is serum.
24. (Previously Presented) The method of Claim 19 wherein the composition is administered in an amount effective to reduce the level of C5a present in a blood-derived fluid of the patient after activation of complement in that fluid.
25. (Previously Presented) The method of Claim 24 wherein the blood-derived fluid is serum.
26. (Previously Presented) The method of Claim 19 wherein the composition is administered in an amount effective to reduce the cell-lysing ability of complement present in the synovial fluid of an inflamed joint of the patient by at least 10%.
27. (Previously Presented) The method of Claim 19 wherein the composition is administered in an amount effective to reduce the level of soluble C5b-9 present in the synovial fluid of an inflamed joint of the patient by at least 10%.
28. (Previously Presented) The method of Claim 19 wherein the composition is administered in an amount effective to reduce the level of C5a present in the synovial fluid of an inflamed joint of the patient by at least 10%.
29. (Previously Presented) The method of Claim 19 comprising the further step, after the administration of the composition, of determining the C5a level and/or the C5b level in the synovial fluid of an inflamed joint of the patient so as to monitor the course of the patient's response to the administration of the composition.

30. (Previously Presented) The method of Claim 29 wherein the C5a level is determined by an immunoassay or a chemotaxis assay.
31. (Previously Presented) The method of Claim 29 wherein the C5b level is determined by measuring the level of soluble C5b-9 in the synovial fluid or by measuring the cell-lysing ability of complement present in the synovial fluid.
32. (Previously Presented) The method of Claim 19 wherein the composition does not interfere with the cleavage of complement component C3 in the patient's serum into C3a and C3b.
33. (Previously Presented) The method of Claim 19, wherein said antibody is a monoclonal antibody.
34. (Previously Presented) The method of Claim 33, wherein said monoclonal antibody is 5G1.1 (ATCC Accession No. HB-11625).